It almost feels like the Trump administration is intentionally breaking the FDA, writes Lab Dish columnist Paul Knoepfler.

With the FDA facing upheaval and personnel exits, former commissioner David Kessler sees an opportunity whereby the agency can make a turn for the better.

How the ouster of key officials at the FDA has created anxiety and uncertainty for the developers of rare disease drugs.

It almost feels like the Trump administration is intentionally breaking the FDA, writes Lab Dish columnist Paul Knoepfler.